Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
Rossana Maffei, Monica Maccaferri, Laura Arletti, et al.
Blood Reviews (2019) Vol. 40, pp. 100635-100635
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.
Leukemia (2020) Vol. 34, Iss. 9, pp. 2354-2363
Open Access | Times Cited: 250
Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky, Nicole Lamanna
Hematology (2020) Vol. 2020, Iss. 1, pp. 336-345
Open Access | Times Cited: 114
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Marzia Palma, Tom A. Mulder, Anders Österborg
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 52
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
Stefania Fiorcari, Rossana Maffei, Daniela Vallerini, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 43
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
Sining Zhu, Samantha Gokhale, Jaeyong Jung, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 36
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia
Sarah Tettamanti, Maria Caterina Rotiroti, Greta Maria Paola Giordano Attianese, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 7, pp. 1566-1579
Open Access | Times Cited: 17
Disseminated fungal infection in a patient receiving zanubrutinib
Madalyn Walsh, Alice Xu, Zuhair K. Ballas, et al.
Clinical Case Reports (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 9
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
Sining Zhu, Jaeyong Jung, Eton Victor, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 23
Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis
Liwei Lv, Xuefei Sun, Yuchen Wu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 21
Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: Improved understanding and new strategic approach with sargramostim
Sherman Chu, Thomas S. McCormick, Hillard M. Lazarus, et al.
Clinical Immunology (2021) Vol. 228, pp. 108731-108731
Open Access | Times Cited: 20
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Francesca Romana Mauro, Diana Giannarelli, Andrea Visentin, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3240-3240
Open Access | Times Cited: 20
COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic
Iwona Hus, Agnieszka Szymczyk, Joanna Mańko, et al.
Biology (2023) Vol. 12, Iss. 4, pp. 545-545
Open Access | Times Cited: 7
Non‐Aspergillus invasive mould infections in patients treated with ibrutinib
Amalia Anastasopoulou, Adam J. DiPippo, Dimitrios P. Kontoyiannis
Mycoses (2020) Vol. 63, Iss. 8, pp. 787-793
Closed Access | Times Cited: 18
BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
Vincenzo Nasillo, Ivana Lagreca, Daniela Vallerini, et al.
Cells (2022) Vol. 11, Iss. 6, pp. 1003-1003
Open Access | Times Cited: 12
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
Haoran Wang, Hao Guo, Jingyi Yang, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 12
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
Shirley D’Sa, J V Matous, Ranjana H. Advani, et al.
Seminars in Hematology (2023) Vol. 60, Iss. 2, pp. 80-89
Open Access | Times Cited: 6
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world study
María Stefania Infante, Ana Fernández‐Cruz, Lucı́a Núñez, et al.
Cancer Medicine (2021) Vol. 10, Iss. 21, pp. 7629-7640
Open Access | Times Cited: 15
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study
Paolo Sportoletti, Luca Laurenti, Annalisa Chiarenza, et al.
Hematological Oncology (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 5
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs
Connor Prosty, Khaled Katergi, Alex Nguyen, et al.
Blood Advances (2023) Vol. 8, Iss. 4, pp. 857-866
Open Access | Times Cited: 5
Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL
Akihiro Ohmoto, Shigeo Fuji
Blood Reviews (2020) Vol. 46, pp. 100738-100738
Closed Access | Times Cited: 14
The Right Dose: From Phase I to Clinical Practice
Stefanie L. Groenland, Mark J. Ratain, Lisa S. Chen, et al.
American Society of Clinical Oncology Educational Book (2021), Iss. 41, pp. 92-106
Open Access | Times Cited: 11
Central nervous system involvement in chronic lymphocytic leukemia: a case report and review of literature
Li-Yuan Qin, Geng Ye, Jian-Feng Mu, et al.
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
Leigh Naylor‐Adamson, Anisha R. Chacko, Zoe Booth, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 10
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study
Andrea Visentin, Vincenzo Nasillo, Monia Marchetti, et al.
HemaSphere (2020) Vol. 4, Iss. 3
Open Access | Times Cited: 9
Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
Stephanos P. Vassilopoulos, Fadi Shehadeh, Markos Kalligeros, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top